Aethlon Medical, Inc. (AEMD) - 10-K Summary
Business Context and Reporting Period
Company: Aethlon Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Fiscal Year Ended: March 31, 2025
Business Overview: Aethlon is a clinical-stage medical therapeutic company developing the Hemopurifier® (HP), an immunotherapeutic device designed to remove harmful extracellular vesicles (EVs) and enveloped viruses from the bloodstream. The FDA has designated the HP as a "Breakthrough Device" for two indications: treatment of advanced/metastatic cancer and treatment of life-threatening viruses without approved therapies.
Key Operational Status: The Company is conducting Phase 1 safety, feasibility, and dose-finding clinical trials in Australia for oncology patients. As of June 2025, three participants have been treated. The Company is also pursuing regulatory approval for a similar trial in India. The Company has no commercial revenue and relies on equity financing to fund operations.
Key Financial Metrics
| Metric | Fiscal Year 2025 | Fiscal Year 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating Expenses | $9,341,365 | $12,636,568 |
| Net Loss | $(13,388,089) | $(12,208,174) |
| Cash and Cash Equivalents (End of Period) | $5,501,261 | $5,441,978 |
| Working Capital | $4,050,514 | $4,395,889 |
| Cash Used in Operating Activities | $(7,645,532) | $(10,129,810) |
| Net Cash Provided by Financing Activities | $7,727,384 | $1,287,605 |
Note: The Net Loss for 2025 includes a non-cash warrant inducement expense of approximately $4.6 million.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately $3.3 million (26%) compared to the prior year. This was driven by reductions in payroll (due to executive departures and workforce reduction), professional fees, and general administrative costs.
- Non-Cash Charges: The 2025 Net Loss increased relative to operating expenses due to a $4.6 million non-cash charge related to a warrant inducement offer in March 2025.
- Capital Raising: The Company raised approximately $7.7 million in net proceeds during FY2025 through a public offering (May 2024) and warrant exercises (including an inducement offer in March 2025). This contrasts with $1.3 million raised in FY2024.
- Stock Split: A 1-for-8 reverse stock split was approved by stockholders in May 2025 and became effective on June 6, 2025, to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The Company's independent auditors have issued a report with an explanatory paragraph expressing substantial doubt about the Company's ability to continue as a going concern. Management states that while cash on hand is approximately $5.5 million, there is substantial doubt that this will carry the company for 12 months beyond the filing date without additional financing.
Outlook: The Company expects to continue to incur losses for the foreseeable future. Future capital requirements depend on the progress of clinical trials, regulatory approvals, and manufacturing scale-up. The Company plans to access equity markets for additional capital, though there is no assurance of success.
Key Risks:
- Regulatory Approval: The Hemopurifier requires FDA Pre-Market Approval (PMA). Delays or failure to obtain approval would prevent commercialization.
- Supply Chain: Manufacturing relies on single-source suppliers for critical components (e.g., GNA lectin, base cartridges). Delays in qualifying new suppliers or interruptions in supply could halt clinical trials.
- Listing Compliance: The Company recently regained compliance with Nasdaq minimum bid price requirements via a reverse stock split. Failure to maintain compliance in the future could result in delisting.
- Internal Controls: The Company previously identified material weaknesses in internal controls (segregation of duties, commission accruals) which management states have been remediated as of March 31, 2025.
Investor Verification Checklist
- Cash Runway: Verify the current cash balance and burn rate to assess the immediate need for additional financing given the "substantial doubt" going concern qualification.
- Clinical Trial Progress: Monitor the Data Safety Monitoring Board (DSMB) recommendations for the Australian oncology trial and the status of regulatory approvals for the India trial.
- Supply Chain Status: Confirm the status of FDA approval for the new supplier of the GNA lectin component, which is critical for manufacturing continuity.
- Stock Liquidity: Review post-split trading volume and price stability to ensure continued compliance with Nasdaq listing rules.
- Dilution Risk: Assess the impact of outstanding warrants and options (over 2.3 million warrants outstanding as of March 31, 2025) on potential future dilution.